New Test Will Make Hepatitis C Diagnosis Easier
WebMD News Archive
July 9, 2001 -- The FDA has approved a new high-tech test aimed at making it easier to diagnose the virus that is the No. 1 cause of liver transplants in the U.S.
Makers of the new test say that it can pinpoint those who are most likely to develop life-threatening complications of hepatitis C. Public health experts say that hepatitis C, called HCV, infects as many as 4.4 million Americans.
The new test, which is called the AMPLICOR HCV Test, will be used to determine if there is "active HCV infection in the blood," said Michael Fried, MD, in a media teleconference Monday to announce the approval. Fried, director of clinical hepatology at the University of North Carolina, Chapel Hill, conducted some of the prelicensing studies of the new test. Roche Diagnostics in Indianapolis developed the test.
HCV is a blood-borne infection that is typically transmitted by transfusion with infected blood -- blood products weren't screened for HCV until the early 1990s -- or by the sharing of needles among injection drug abusers. The CDC estimates that HCV causes about 10,000 deaths each year but says that figure is likely to climb to 38,000 by end of this decade.
Most people who are infected with HCV have no symptoms for many years, says Fried. About 15% of people who are infected with HCV recover in about six months, but the rest develop chronic HCV infection. Among those with chronic infection, about 20% to 30% develop progressive liver disease, meaning that the disease causes cirrhosis, which can lead to liver failure and the need for a transplant. HCV is also associated with liver cancer.
One of the real difficulties in diagnosing and treating the disease is sorting out those who have been exposed but will recover from those who have chronic infection, and finally identifying those who have the greatest risk for progressive disease. The key to this sorting process, says Fried, can be found inside the cells that are exposed to the virus.
The first step is standard screening, which is done with a blood test that checks blood for the presence of HCV antibodies. "The antibody test will remain the first line screening test," says Fried.